Lucid Diagnostics, Inc.
(NASDAQ : LUCD)

( )
LUCD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. -0.60%544.971.0%$621.91m
ABTAbbott Laboratories -0.91%109.220.8%$585.36m
DHRDanaher Corp. -0.98%255.530.7%$572.59m
MDTMedtronic Plc -0.93%90.530.6%$550.73m
ISRGIntuitive Surgical, Inc. 0.32%206.750.8%$422.25m
BSXBoston Scientific Corp. -0.55%37.801.0%$341.88m
ALGNAlign Technology, Inc. 2.74%254.116.4%$295.06m
BDXBecton, Dickinson & Co. -1.50%248.031.0%$283.25m
SYKStryker Corp. -0.94%201.951.3%$280.50m
EWEdwards Lifesciences Corp. 0.65%98.020.4%$264.78m
IDXXIDEXX Laboratories, Inc. 2.35%366.873.8%$229.07m
BAXBaxter International, Inc. -0.23%65.341.8%$205.69m
AAgilent Technologies, Inc. 1.09%120.511.7%$197.45m
DXCMDexCom, Inc. 1.07%78.461.9%$197.40m
SWAVShockwave Medical, Inc. 1.61%201.820.0%$184.35m

Company Profile

Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.